These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7805221)
1. Association between ease of suppression of ventricular arrhythmia and survival. Goldstein S; Brooks MM; Ledingham R; Kennedy HL; Epstein AE; Pawitan Y; Bigger JT Circulation; 1995 Jan; 91(1):79-83. PubMed ID: 7805221 [TBL] [Abstract][Full Text] [Related]
2. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Anderson JL; Platia EV; Hallstrom A; Henthorn RW; Buckingham TA; Carlson MD; Carson PE Circulation; 1994 Dec; 90(6):2843-52. PubMed ID: 7994829 [TBL] [Abstract][Full Text] [Related]
3. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). Epstein AE; Hallstrom AP; Rogers WJ; Liebson PR; Seals AA; Anderson JL; Cohen JD; Capone RJ; Wyse DG JAMA; 1993 Nov; 270(20):2451-5. PubMed ID: 8230622 [TBL] [Abstract][Full Text] [Related]
4. Effects of advancing age on the efficacy and side effects of antiarrhythmic drugs in post-myocardial infarction patients with ventricular arrhythmias. The CAST Investigators. Akiyama T; Pawitan Y; Campbell WB; Papa L; Barker AH; Rubbert P; Friedman L; Keller M; Josephson RA J Am Geriatr Soc; 1992 Jul; 40(7):666-72. PubMed ID: 1607582 [TBL] [Abstract][Full Text] [Related]
5. Predicting mortality after myocardial infarction from the response of RR variability to antiarrhythmic drug therapy. Bigger JT; Rolnitzky LM; Steinman RC; Fleiss JL J Am Coll Cardiol; 1994 Mar; 23(3):733-40. PubMed ID: 7509355 [TBL] [Abstract][Full Text] [Related]
6. The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. Greene HL; Roden DM; Katz RJ; Woosley RL; Salerno DM; Henthorn RW J Am Coll Cardiol; 1992 Apr; 19(5):894-8. PubMed ID: 1552108 [TBL] [Abstract][Full Text] [Related]
7. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in the entire population enrolled. Epstein AE; Bigger JT; Wyse DG; Romhilt DW; Reynolds-Haertle RA; Hallstrom AP J Am Coll Cardiol; 1991 Jul; 18(1):14-9. PubMed ID: 1904891 [TBL] [Abstract][Full Text] [Related]
8. Circadian pattern of arrhythmic death in patients receiving encainide, flecainide or moricizine in the Cardiac Arrhythmia Suppression Trial (CAST). Peters RW; Mitchell LB; Brooks MM; Echt DS; Barker AH; Capone R; Liebson PR; Greene HL J Am Coll Cardiol; 1994 Feb; 23(2):283-9. PubMed ID: 8294678 [TBL] [Abstract][Full Text] [Related]
9. Events in the cardiac arrhythmia suppression trial: baseline predictors of mortality in placebo-treated patients. Capone RJ; Pawitan Y; el-Sherif N; Geraci TS; Handshaw K; Morganroth J; Schlant RC; Waldo AL J Am Coll Cardiol; 1991 Nov; 18(6):1434-8. PubMed ID: 1939943 [TBL] [Abstract][Full Text] [Related]
10. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice. Kellen JC; Ettinger A; Todd L; Brezsnyak ML; Campion J; McBride R; Thomas S; Corum J; Schron E Am J Crit Care; 1996 Jan; 5(1):19-25. PubMed ID: 8680488 [TBL] [Abstract][Full Text] [Related]
11. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Cardiac Arrhythmia Pilot Study (CAPS) Investigators Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169 [TBL] [Abstract][Full Text] [Related]
12. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. Cardiac Arrhythmia Suppression Trial (CAST) Investigators N Engl J Med; 1989 Aug; 321(6):406-12. PubMed ID: 2473403 [TBL] [Abstract][Full Text] [Related]
13. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment. Bigger JT Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253 [TBL] [Abstract][Full Text] [Related]
14. Treatment of ventricular arrhythmias after CAST. Tonkin AM Med J Aust; 1992 Apr; 156(7):488-92. PubMed ID: 1372950 [TBL] [Abstract][Full Text] [Related]
15. A critical appraisal of the cardiac arrhythmia suppression trial (CAST). Naccarelli GV; Dougherty AH; Wolbrette D; Wiggins S Appl Cardiopulm Pathophysiol; 1991; 4(1):9-16. PubMed ID: 10147539 [TBL] [Abstract][Full Text] [Related]
16. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. Cardiac Arrhythmia Suppression Trial II Investigators N Engl J Med; 1992 Jul; 327(4):227-33. PubMed ID: 1377359 [TBL] [Abstract][Full Text] [Related]
17. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Akiyama T; Pawitan Y; Greenberg H; Kuo CS; Reynolds-Haertle RA Am J Cardiol; 1991 Dec; 68(17):1551-5. PubMed ID: 1720917 [TBL] [Abstract][Full Text] [Related]
18. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. Echt DS; Liebson PR; Mitchell LB; Peters RW; Obias-Manno D; Barker AH; Arensberg D; Baker A; Friedman L; Greene HL N Engl J Med; 1991 Mar; 324(12):781-8. PubMed ID: 1900101 [TBL] [Abstract][Full Text] [Related]
19. The Cardiac Arrhythmia Suppression Trial: background, interim results and implications. Pratt CM; Moye LA Am J Cardiol; 1990 Jan; 65(4):20B-29B. PubMed ID: 2105049 [TBL] [Abstract][Full Text] [Related]
20. Psychosocial predictors of mortality in the Cardiac Arrhythmia Suppression Trial-1 (CAST-1). Gorkin L; Schron EB; Brooks MM; Wiklund I; Kellen J; Verter J; Schoenberger JA; Pawitan Y; Morris M; Shumaker S Am J Cardiol; 1993 Feb; 71(4):263-7. PubMed ID: 8427165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]